- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05443451
BETTY: Iperplasia prostatica benigna Terapia a microonde mirata transperineale
Ablazione con ago a microonde transperineale guidata da ultrasuoni 3D per uomini con iperplasia prostatica benigna sintomatica
This is a pilot study on applying 3D-Ultrasound-Guided Transperineal Microwave needle ablation for men with symptomatic benign prostatic hyperplasia (BPH).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, single centre, open-label and non-comparative trial planned on 12 patients. Patients who fit inclusion criteria would be recruited and offered microwave ablation to the enlarged prostate. The patients will be closely followed up to 6 months after treatment with serial assessment on safety and efficacy.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age over 50 years.
- Benign prostatic hyperplasia with prostate size 30-80 cc
- IPSS ≥ 14
- PSA ≤ 4 ng/mL or PSA >4 ng/mL with no evidence of suspicious lesion on mpMRI
- Maximum urine flow rate (Qmax) ≤ 15 mL/s.
- Post-Void Residual ≤ 150 mL.
- Patient suitable for IV sedation and/or spinal anaesthesia and/or general anaesthesia and focal microwave ablation.
- Informed written consent
Exclusion Criteria:
- Significant intravesical median lobe hyperplasia.
- Suspicious lesion on mpMRI prostate
- History of prostate, bladder or urethral surgery.
- History of prostate cancer
- Presence of stones, bladder diverticulum and/or bladder tumor
- History of long-term indwelling catheter.
- Urethral stricture
- Known coagulopathy or on anticoagulant
- Presence of a pacemaker.
- Active infection
- Dysuria due to bladder dysfunction.
- Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit.
- Neurological disorders that would impact bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury).
- Contraindications for mpMRI exam or MR contrast
- Acute and/or chronic renal failure (GFR <50 ml/min and serum creatinine > 1.5 mg/d).
- Patient currently participating in another interventional clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Ablazione transperineale con ago a microonde per IPB sintomatico
|
The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adverse events (AE) and serious adverse events (SAE) related to the treatment
Lasso di tempo: At 1 month
|
The severity of AE is grade by Clavien-Dindo classification. |
At 1 month
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prostate volume change
Lasso di tempo: Baseline, 3 months, 6 months
|
Prostate volume change after treatment |
Baseline, 3 months, 6 months
|
|
Urinary symptoms measured by International Prostate Symptom Score (IPSS) score
Lasso di tempo: Baseline, 1 month, 3 months, 6 months
|
Change in total scores in International Prostate Symptom Score (ranges from 0 to 35) questionnaires. The higher score, the more worse symptom. |
Baseline, 1 month, 3 months, 6 months
|
|
Erectile function measured by International Index of Erectile Function 5-item version (IIEF-5) score
Lasso di tempo: Baseline, 1 month, 3 months, 6 months
|
Change in International Index of Erectile Function 5 questionnaire score (ranges from 0 to 25). The higher score, the more worse symptom. |
Baseline, 1 month, 3 months, 6 months
|
|
Ejaculatory function measured by MSHQ-EjD-SF (function and bother) score
Lasso di tempo: Baseline, 1 month, 3 months, 6 months
|
Change in MSHQ-EjD-SF questionnaire score (Range from 1-15 for function and and 0-5 for bother). The higher score, the more worse symptom. |
Baseline, 1 month, 3 months, 6 months
|
|
Change in urodynamic in uroflowmetry
Lasso di tempo: Baseline, 1 month, 3 months, 6 months
|
Change in urodynamic function assessed by uroflowmetry, parameters include voided volume, maximum flow rate and post-void residual. |
Baseline, 1 month, 3 months, 6 months
|
|
PSA change
Lasso di tempo: Baseline, 3 months, 6 months
|
PSA change after treatment |
Baseline, 3 months, 6 months
|
|
Average patient post-operative pain level
Lasso di tempo: Baseline, 2 and 4 hours after the procedure and at 1-week
|
Assessed by a pain numeric rating scale, Score 0-10, the higher score the worsen pain |
Baseline, 2 and 4 hours after the procedure and at 1-week
|
|
Patient quality of life
Lasso di tempo: Baseline, 1-week, 1-month, 3-month, and 6-month,
|
Assessed with the EQ-5D-5L questionnaire, the higher the score the better in quality of life |
Baseline, 1-week, 1-month, 3-month, and 6-month,
|
|
Patient satisfaction
Lasso di tempo: Baseline, 1-week, 1-month, 3-month, and 6-month,
|
Assessed with the PGI-I questionnaire,the lower score the more satisfaction |
Baseline, 1-week, 1-month, 3-month, and 6-month,
|
|
Ease of the procedure measured with a score chosen by the operator
Lasso di tempo: Post procedure immediately
|
1: easy, 2: moderate, 3: difficult |
Post procedure immediately
|
|
Ablation treatment time
Lasso di tempo: Intra-operation
|
Duration of the ablation procedure |
Intra-operation
|
|
Length of hospital stay
Lasso di tempo: The total number of days of hospitalization for this surgical procedure up to day 30 after the procedure]
|
Total number of days of hospitalization for the surgical procedure |
The total number of days of hospitalization for this surgical procedure up to day 30 after the procedure]
|
|
Operation time
Lasso di tempo: Intra-operation
|
Duration of patients stay in Operation Room |
Intra-operation
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Peter Ka-Fung CHIU, FRCS, PhD, Chinese University of Hong Kong
Pubblicazioni e link utili
Pubblicazioni generali
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.
- Chiu PK, Lo KL, Teoh JY, Ma SF, Leung CH, Wong HF, Li KM, Sae-Lo K, Kwok SW, Li SY, Yee CH, Hou SM, Ng CF. Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):431-438. doi: 10.1038/s41391-020-00293-1. Epub 2020 Sep 30.
- Chughtai B, Elterman D, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terrens W, Kohan A, Gonzalez RR, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu LM, Alshak MN, Kaminetzky J. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. 2021 Jul;153:270-276. doi: 10.1016/j.urology.2020.12.022. Epub 2020 Dec 26.
- Zhang W, Zhang X, Li H, Wu F, Wang H, Zhao M, Hu H, Xu K. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study. BMJ Open. 2019 Jun 19;9(6):e022792. doi: 10.1136/bmjopen-2018-022792.
- Ng CF, Yee CH, Chan CK, Wong HM, Chiu PK, Tsu JH, Teoh JY, Ho KL. Bipolar transurethral vapourisation versus monopolar transurethral resection of prostate: a randomised controlled trial. Hong Kong Med J. 2017 Jun;23 Suppl 2(3):32-34. No abstract available.
- Yee CH, Wong JH, Chiu PK, Chan CK, Lee WM, Tsu JH, Teoh JY, Ng CF. Short-stay transurethral prostate surgery: A randomized controlled trial comparing transurethral resection in saline bipolar transurethral vaporization of the prostate with monopolar transurethral resection. Asian J Endosc Surg. 2015 Aug;8(3):316-22. doi: 10.1111/ases.12197. Epub 2015 Jun 3.
- Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, Schatzl G; Prostate Study Group of the Austrian Society of Urology. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol. 2005 Apr;47(4):499-504. doi: 10.1016/j.eururo.2004.12.010. Epub 2005 Jan 23.
- Raizenne BL, Zheng X, Mao J, Zorn KC, Cho A, Elterman D, Bhojani N, Sedrakyan A, Chughtai B. Real-world data comparing minimally invasive surgeries for benign prostatic hyperplasia. World J Urol. 2022 May;40(5):1185-1193. doi: 10.1007/s00345-021-03926-9. Epub 2022 Feb 2.
- McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Pliskin M, Beahrs JR, Prall D, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Tadros NN, Gange SN, Roehrborn CG. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021 Sep;206(3):715-724. doi: 10.1097/JU.0000000000001778. Epub 2021 Apr 19.
- Barry Delongchamps N, Schull A, Anract J, Abecassis JP, Zerbib M, Sibony M, Jilet L, Abdoul H, Goffin V, Peyromaure M. Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS One. 2021 Jul 14;16(7):e0252040. doi: 10.1371/journal.pone.0252040. eCollection 2021.
- Lo KL, Chui KL, Leung CH, Ma SF, Lim K, Ng T, Wong J, Li JKM, Mak SK, Ng CF. Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy. Hong Kong Med J. 2019 Jun;25(3):209-215. doi: 10.12809/hkmj187599. Epub 2019 May 29.
- Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CRE 2022.249
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .